Long-acting octreotide treatment causes a sustained decrease in ghrelin concentrations but does not affect weight, behaviour and appetite in subjects with Prader-Willi syndrome.

De Waele K, Ishkanian SL, Bogarin R, Miranda CA, Ghatei MA, Bloom SR, Pacaud D, Chanoine JP

European journal of endocrinology4 Jul 2008Cited by 46 (Europe PMC)

PMID18603572DOI10.1530/eje-08-0462PepBankPUB-18603572

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanNon-randomized trialEfficacy outcome
In adolescents with Prader-Willi syndrome, octreotide decreased fasting acylated ghrelin by 53% (P<0.05).
In plain wordsIn adolescents with Prader-Willi syndrome, octreotide lowered fasting acylated ghrelin.
Peptide
Octreotide
Outcome
DecreaseFasting acylated ghrelin
Study
n = 8
Outcome group
Appetite and food intake · Endocrine and hormones
Studied dose
30 mg every 4 weeks · intramuscular · 16 weeksAs given in this study (human).
Measurements
Change in fasting acylated ghrelin
−53%
octreotide
Source sentences
Summary
Oct caused a decrease in both acylated (-53%) and desacyl (-54%) fasting ghrelin concentrations (P<0.05) but did not significantly affect BMI.
3 context sentences(design, population, supporting numbers)
Summary · context
A 56-week prospective, randomized, cross-over trial.
Summary · context
Nine subjects with PWS (age 14.6 (10.8-18.9) years, body mass index (BMI) Z-score +1.9 (0.6-3.0)) received either Oct (30 mg) or saline i.m. every 4 weeks for 16 weeks and were switched over to the other treatment after a 24-week washout period.
Summary · context
Eight subjects completed the study.
Report a problemFND-1860357201
02HumanNon-randomized trialEfficacy outcome
In adolescents with Prader-Willi syndrome, octreotide decreased fasting desacyl ghrelin by 54% (P<0.05).
In plain wordsIn adolescents with Prader-Willi syndrome, octreotide lowered fasting desacyl ghrelin.
Peptide
Octreotide
Outcome
DecreaseFasting desacyl ghrelin
Study
n = 8
Outcome group
Appetite and food intake · Endocrine and hormones
Studied dose
30 mg every 4 weeks · intramuscular · 16 weeksAs given in this study (human).
Measurements
Change in fasting desacyl ghrelin
−54%
octreotide
Source sentences
Summary
Oct caused a decrease in both acylated (-53%) and desacyl (-54%) fasting ghrelin concentrations (P<0.05) but did not significantly affect BMI.
3 context sentences(design, population, supporting numbers)
Summary · context
A 56-week prospective, randomized, cross-over trial.
Summary · context
Nine subjects with PWS (age 14.6 (10.8-18.9) years, body mass index (BMI) Z-score +1.9 (0.6-3.0)) received either Oct (30 mg) or saline i.m. every 4 weeks for 16 weeks and were switched over to the other treatment after a 24-week washout period.
Summary · context
Eight subjects completed the study.
Report a problemFND-1860357202
03HumanNon-randomized trialEfficacy outcome
In adolescents with Prader-Willi syndrome, octreotide did not significantly affect BMI.
In plain wordsIn adolescents with Prader-Willi syndrome, octreotide did not significantly change BMI.
Peptide
Octreotide
Outcome
No significant changeBMI
Study
n = 8
Outcome group
Body weight · Metabolic and weight
Studied dose
30 mg every 4 weeks · intramuscular · 16 weeksAs given in this study (human).
Source sentences
Summary
Oct caused a decrease in both acylated (-53%) and desacyl (-54%) fasting ghrelin concentrations (P<0.05) but did not significantly affect BMI.
3 context sentences(design, population, supporting numbers)
Summary · context
A 56-week prospective, randomized, cross-over trial.
Summary · context
Nine subjects with PWS (age 14.6 (10.8-18.9) years, body mass index (BMI) Z-score +1.9 (0.6-3.0)) received either Oct (30 mg) or saline i.m. every 4 weeks for 16 weeks and were switched over to the other treatment after a 24-week washout period.
Summary · context
Eight subjects completed the study.
Report a problemFND-1860357203
04HumanNon-randomized trialEfficacy outcome
In adolescents with Prader-Willi syndrome, octreotide did not significantly affect peptide YY concentrations.
In plain wordsIn adolescents with Prader-Willi syndrome, octreotide did not significantly change peptide YY levels.
Peptide
Octreotide
Outcome
No significant changePeptide YY
Study
n = 8
Outcome group
Appetite and food intake · Endocrine and hormones
Studied dose
30 mg every 4 weeks · intramuscular · 16 weeksAs given in this study (human).
Source sentences
Summary
Oct had no significant effect on peptide YY concentrations, appetite or compulsive behaviour towards food.
3 context sentences(design, population, supporting numbers)
Summary · context
A 56-week prospective, randomized, cross-over trial.
Summary · context
Nine subjects with PWS (age 14.6 (10.8-18.9) years, body mass index (BMI) Z-score +1.9 (0.6-3.0)) received either Oct (30 mg) or saline i.m. every 4 weeks for 16 weeks and were switched over to the other treatment after a 24-week washout period.
Summary · context
Eight subjects completed the study.
Report a problemFND-1860357204
05HumanNon-randomized trialEfficacy outcome
In adolescents with Prader-Willi syndrome, octreotide did not significantly affect appetite.
In plain wordsIn adolescents with Prader-Willi syndrome, octreotide did not significantly change appetite.
Peptide
Octreotide
Outcome
No significant changeAppetite
Study
n = 8
Outcome group
Appetite and food intake · Endocrine and hormones
Studied dose
30 mg every 4 weeks · intramuscular · 16 weeksAs given in this study (human).
Source sentences
Summary
Oct had no significant effect on peptide YY concentrations, appetite or compulsive behaviour towards food.
3 context sentences(design, population, supporting numbers)
Summary · context
A 56-week prospective, randomized, cross-over trial.
Summary · context
Nine subjects with PWS (age 14.6 (10.8-18.9) years, body mass index (BMI) Z-score +1.9 (0.6-3.0)) received either Oct (30 mg) or saline i.m. every 4 weeks for 16 weeks and were switched over to the other treatment after a 24-week washout period.
Summary · context
Eight subjects completed the study.
Report a problemFND-1860357205
06HumanNon-randomized trialEfficacy outcome
In adolescents with Prader-Willi syndrome, octreotide did not significantly affect compulsive behavior towards food.
In plain wordsIn adolescents with Prader-Willi syndrome, octreotide did not significantly change compulsive food behavior.
Peptide
Octreotide
Outcome
No significant changeCompulsive food behavior
Study
n = 8
Outcome group
Appetite and food intake · Endocrine and hormones
Studied dose
30 mg every 4 weeks · intramuscular · 16 weeksAs given in this study (human).
Source sentences
Summary
Oct had no significant effect on peptide YY concentrations, appetite or compulsive behaviour towards food.
3 context sentences(design, population, supporting numbers)
Summary · context
A 56-week prospective, randomized, cross-over trial.
Summary · context
Nine subjects with PWS (age 14.6 (10.8-18.9) years, body mass index (BMI) Z-score +1.9 (0.6-3.0)) received either Oct (30 mg) or saline i.m. every 4 weeks for 16 weeks and were switched over to the other treatment after a 24-week washout period.
Summary · context
Eight subjects completed the study.
Report a problemFND-1860357206
07HumanNon-randomized trialEfficacy outcome
In adolescents with Prader-Willi syndrome, octreotide decreased IGF-I concentrations.
In plain wordsIn adolescents with Prader-Willi syndrome, octreotide lowered IGF-I levels.
Peptide
Octreotide
Outcome
DecreaseIGF-I
Study
n = 8
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
30 mg every 4 weeks · intramuscular · 16 weeksAs given in this study (human).
Source sentences
Summary
Oct caused a decrease in insulin-like growth factor-I concentrations, an increase in HbA1c and transient elevation of blood glucose in two subjects.
3 context sentences(design, population, supporting numbers)
Summary · context
A 56-week prospective, randomized, cross-over trial.
Summary · context
Nine subjects with PWS (age 14.6 (10.8-18.9) years, body mass index (BMI) Z-score +1.9 (0.6-3.0)) received either Oct (30 mg) or saline i.m. every 4 weeks for 16 weeks and were switched over to the other treatment after a 24-week washout period.
Summary · context
Eight subjects completed the study.
Report a problemFND-1860357207
08HumanNon-randomized trialSafety outcome
In adolescents with Prader-Willi syndrome, octreotide increased HbA1c.
In plain wordsIn adolescents with Prader-Willi syndrome, octreotide increased HbA1c.
Peptide
Octreotide
Outcome
IncreaseHbA1c
Study
n = 8
Outcome group
Glycemic control · Metabolic and weight
Studied dose
30 mg every 4 weeks · intramuscular · 16 weeksAs given in this study (human).
Source sentences
Summary
Oct caused a decrease in insulin-like growth factor-I concentrations, an increase in HbA1c and transient elevation of blood glucose in two subjects.
3 context sentences(design, population, supporting numbers)
Summary · context
A 56-week prospective, randomized, cross-over trial.
Summary · context
Nine subjects with PWS (age 14.6 (10.8-18.9) years, body mass index (BMI) Z-score +1.9 (0.6-3.0)) received either Oct (30 mg) or saline i.m. every 4 weeks for 16 weeks and were switched over to the other treatment after a 24-week washout period.
Summary · context
Eight subjects completed the study.
Report a problemFND-1860357208
09HumanNon-randomized trialSafety outcome
In Prader-Willi syndrome, octreotide caused transient blood glucose elevation in two subjects.
In plain wordsIn Prader-Willi syndrome, two subjects had temporarily increased blood sugar with octreotide.
Peptide
Octreotide
Outcome
IncreaseTransient blood glucose elevation
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
30 mg every 4 weeks · intramuscular · 16 weeksAs given in this study (human).
Measurements
Subjects with transient blood glucose elevation
2 subjects
octreotide
Source sentences
Summary
Oct caused a decrease in insulin-like growth factor-I concentrations, an increase in HbA1c and transient elevation of blood glucose in two subjects.
3 context sentences(design, population, supporting numbers)
Summary · context
A 56-week prospective, randomized, cross-over trial.
Summary · context
Nine subjects with PWS (age 14.6 (10.8-18.9) years, body mass index (BMI) Z-score +1.9 (0.6-3.0)) received either Oct (30 mg) or saline i.m. every 4 weeks for 16 weeks and were switched over to the other treatment after a 24-week washout period.
Summary · context
Eight subjects completed the study.
Report a problemFND-1860357209
10HumanNon-randomized trialSafety outcome
In the octreotide trial in Prader-Willi syndrome, three subjects developed gallstones.
In plain wordsIn the octreotide trial in Prader-Willi syndrome, three subjects developed gallstones.
Peptide
Octreotide
Outcome
Not applicableGallstones
Study
n: not reported in source
Outcome group
Adverse events · Gastrointestinal
Studied dose
30 mg every 4 weeks · intramuscular · 16 weeksAs given in this study (human).
Measurements
Subjects who developed gallstones
3 subjects
octreotide trial
Source sentences
Summary
Three subjects developed gallstones.
3 context sentences(design, population, supporting numbers)
Summary · context
A 56-week prospective, randomized, cross-over trial.
Summary · context
Nine subjects with PWS (age 14.6 (10.8-18.9) years, body mass index (BMI) Z-score +1.9 (0.6-3.0)) received either Oct (30 mg) or saline i.m. every 4 weeks for 16 weeks and were switched over to the other treatment after a 24-week washout period.
Summary · context
Eight subjects completed the study.
Report a problemFND-1860357210

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.